ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.38
0.74%
US Tech 100
20,836.00
1.31%
S&P 500
5,930.85
1.09%
US Dollar vs CAD
1.43226
0.00%
Bitcoin
98,607.86
0.87%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Lantern Pharma Inc (LTRN)

  7. Lantern Pharma Inc (LTRN) News

LTRN

Lantern Pharma (LTRN)

Lantern Pharma Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LTRN
DateTimeSourceHeadlineSymbolCompany
12/09/20247:15AMBusiness WireLantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC PatientsNASDAQ:LTRNLantern Pharma Inc
12/03/20247:00AMBusiness WireLantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)NASDAQ:LTRNLantern Pharma Inc
11/26/20247:45AMBusiness WireLantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic LethalityNASDAQ:LTRNLantern Pharma Inc
11/19/20247:00AMBusiness WireLantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC PatientsNASDAQ:LTRNLantern Pharma Inc
11/07/20243:07PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LTRNLantern Pharma Inc
11/07/20243:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LTRNLantern Pharma Inc
11/07/20243:05PMBusiness WireLantern Pharma Reports Third Quarter 2024 Financial Results and Business UpdatesNASDAQ:LTRNLantern Pharma Inc
11/05/20247:00AMBusiness WireStarlight Therapeutics Announces Inaugural Members of Scientific Advisory BoardNASDAQ:LTRNLantern Pharma Inc
10/31/20247:00AMBusiness WireLantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ETNASDAQ:LTRNLantern Pharma Inc
10/23/20247:45AMBusiness WireLantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024NASDAQ:LTRNLantern Pharma Inc
10/21/20247:00AMBusiness WireLantern Pharma to Host & Participate in Two Public Webinars During OctoberNASDAQ:LTRNLantern Pharma Inc
10/15/20248:07AMBusiness WireLantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDANASDAQ:LTRNLantern Pharma Inc
09/23/20247:00AMBusiness WireLantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s CancersNASDAQ:LTRNLantern Pharma Inc
08/08/20243:07PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LTRNLantern Pharma Inc
08/08/20243:01PMBusiness WireLantern Pharma Reports Second Quarter 2024 Financial Results and Business UpdatesNASDAQ:LTRNLantern Pharma Inc
08/07/20248:31AMBusiness Wire Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024NASDAQ:LTRNLantern Pharma Inc
08/05/20247:00AMBusiness WireLantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient CohortNASDAQ:LTRNLantern Pharma Inc
08/01/20247:00AMBusiness WireLantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ETNASDAQ:LTRNLantern Pharma Inc
07/17/20243:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LTRNLantern Pharma Inc
07/17/20243:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LTRNLantern Pharma Inc
07/17/20243:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LTRNLantern Pharma Inc
07/17/20243:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LTRNLantern Pharma Inc
07/10/20247:30AMBusiness WireLantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184NASDAQ:LTRNLantern Pharma Inc
06/17/20243:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LTRNLantern Pharma Inc
06/12/20246:30AMBusiness WireLantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284NASDAQ:LTRNLantern Pharma Inc
06/10/202411:16PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LTRNLantern Pharma Inc
05/24/20243:09PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LTRNLantern Pharma Inc
05/24/20243:08PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LTRNLantern Pharma Inc
05/24/20243:06PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LTRNLantern Pharma Inc
05/13/202412:30AMBusiness WireOregon Therapeutics et Lantern Pharma lancent une collaboration stratégique dans le domaine de l’intelligence artificielle pour optimiser le développement du XCE853, premier candidat médicament de sa catégorie, un puissant inhibiteur...NASDAQ:LTRNLantern Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:LTRN

Your Recent History

USOTC
GRLT
Grillit (PK)
USOTC
RDAR
Raadr (PK)
USOTC
AFFU
Affluence (PK)
USOTC
MGON
Megola (PK)
USOTC
IFUS
Impact Fusion (PK)
NASDAQ
NXPL
NextPlat
USOTC
CBRF
CyberFuels (PK)
USOTC
PHIL
PHI (PK)
USOTC
GTCH
GBT Technologies (PK)
NYSE
IONQ
IonQ
NASDAQ
ILLR
Triller
USOTC
SPZI
Spooz (PK)
AMEX
KULR
KULR Technology
USOTC
AXXA
Exxe (PK)
COIN
SHIBUSD
SHIBA INU
USOTC
MONI
Moon Equity (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads